A Review of Hepatorenal Syndrome

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2021 Aug 9

PMID 34367745

Citations 9

Authors

Abinash Subedi

Vishnu Charan Suresh Kumar

Aakritee Sharma Subedi

Bishnu Sapkota

Affiliations

Soon will be listed here.

Abstract

The development of acute kidney injury (AKI) is one of the most frequent complications in patients with cirrhosis. AKI due to volume depletion is the most common etiology and hepatorenal syndrome (HRS) is the second most common cause of AKI in these patients. HRS is the extreme form of kidney injury in patients with cirrhosis, which is caused due to a reduction in renal blood flow unresponsive to volume expansion.The literature involving HRS is rapidly evolving and newer tests and updated definitions have been proposed which allows timely identification and treatment. Here, we will discuss the definition, pathophysiology, prevention, diagnosis, and treatment of HRS.

Citing Articles

Readmission Rate, Predictors, Outcomes, and Burden of Readmission of Hepatorenal Syndrome in the United States: A Nationwide Analysis.

Sohail A, Chaudhary A, Bhinder M, Zahid K, Brown K JGH Open. 2024; 8(11):e70062.

PMID: 39600414 PMC: 11588588. DOI: 10.1002/jgh3.70062.

A Study of the Clinical Profiles of Patients With Hepatorenal Syndrome.

Borle A, Kanitkar S, Bagare P, Ahlawat M, Ande S Cureus. 2024; 16(8):e66778.

PMID: 39268272 PMC: 11392026. DOI: 10.7759/cureus.66778.

Clinical Implications of Inflammation in Patients With Cirrhosis.

Kronsten V, Shawcross D Am J Gastroenterol. 2024; 120(1):65-74.

PMID: 39194320 PMC: 11676607. DOI: 10.14309/ajg.0000000000003056.

Advances in the management of complications from cirrhosis.

Singh J, Ebaid M, Saab S Gastroenterol Rep (Oxf). 2024; 12:goae072.

PMID: 39104730 PMC: 11299547. DOI: 10.1093/gastro/goae072.

Management of hepatorenal syndrome and associated outcomes: a systematic reviews.

Roozbeh J, Jahromi S, Rezazadeh M, Hamidianjahromi A, Malekmakan L BMJ Open Gastroenterol. 2024; 11(1).

PMID: 38631807 PMC: 11033346. DOI: 10.1136/bmjgast-2023-001319.

References

Martin-Llahi M, Pepin M, Guevara M, Diaz F, Torre A, Monescillo A . Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008; 134(5):1352-9. DOI: 10.1053/j.gastro.2008.02.024. View

Gines P, Uriz J, Calahorra B, Garcia-Tsao G, Kamath P, Del Arbol L . Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology. 2002; 123(6):1839-47. DOI: 10.1053/gast.2002.37073. View

de Carvalho J, Villela-Nogueira C, Luiz R, Guzzo P, Rosa J, Rocha E . Acute kidney injury network criteria as a predictor of hospital mortality in cirrhotic patients with ascites. J Clin Gastroenterol. 2011; 46(3):e21-6. DOI: 10.1097/MCG.0b013e31822e8e12. View

Ruiz-Del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V . Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005; 42(2):439-47. DOI: 10.1002/hep.20766. View

Gines P, Tito L, Arroyo V, Planas R, Panes J, Viver J . Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988; 94(6):1493-502. DOI: 10.1016/0016-5085(88)90691-9. View

Azoulay D, Castaing D, Majno P, Saliba F, Ichai P, Smail A . Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol. 2001; 35(5):590-7. DOI: 10.1016/s0168-8278(01)00185-4. View

Simonetto D, Gines P, Kamath P . Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ. 2020; 370:m2687. DOI: 10.1136/bmj.m2687. View

Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A . Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012; 56(6):1293-8. DOI: 10.1016/j.jhep.2012.01.012. View

De Franchis R . Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015; 63(3):743-52. DOI: 10.1016/j.jhep.2015.05.022. View

10.

Belcher J, Garcia-Tsao G, Sanyal A, Bhogal H, Lim J, Ansari N . Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology. 2012; 57(2):753-62. PMC: 3390443. DOI: 10.1002/hep.25735. View

11.

Merkel C, Gatta A, Zuin R, Finucci G, Nosadini R, Ruol A . Effect of somatostatin on splanchnic hemodynamics in patients with liver cirrhosis and portal hypertension. Digestion. 1985; 32(2):92-8. DOI: 10.1159/000199224. View

12.

Alessandria C, Debernardi Venon W, Marzano A, Barletti C, Fadda M, Rizzetto M . Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2. Eur J Gastroenterol Hepatol. 2002; 14(12):1363-8. DOI: 10.1097/00042737-200212000-00013. View

13.

Bortoluzzi A, Ceolotto G, Gola E, Sticca A, Bova S, Morando F . Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. Hepatology. 2012; 57(1):266-76. DOI: 10.1002/hep.26021. View

14.

Pomier-Layrargues G, Paquin S, Hassoun Z, Lafortune M, Tran A . Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. Hepatology. 2003; 38(1):238-43. DOI: 10.1053/jhep.2003.50276. View

15.

Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S . Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology. 1998; 28(4):937-43. DOI: 10.1002/hep.510280407. View

16.

Laterre P, Berry S, Blemings A, Carlsen J, Francois B, Graves T . Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial. JAMA. 2019; 322(15):1476-1485. PMC: 6802260. DOI: 10.1001/jama.2019.14607. View

17.

Caregaro L, Menon F, Angeli P, Amodio P, Merkel C, Bortoluzzi A . Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med. 1994; 154(2):201-5. View

18.

Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Castells L . Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999; 341(6):403-9. DOI: 10.1056/NEJM199908053410603. View

19.

Zhang W, Frei B . Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. Cardiovasc Res. 2002; 55(4):820-9. DOI: 10.1016/s0008-6363(02)00492-3. View

20.

Arroyo V, Gines P, Gerbes A, DUDLEY F, Gentilini P, Laffi G . Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology. 1996; 23(1):164-76. DOI: 10.1002/hep.510230122. View